Drug Type Radionuclide Drug Conjugates (RDC), Therapeutic radiopharmaceuticals |
Synonyms ABY 271, ABY271, [177]Lu-ABY-271 |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | SE | 07 Jun 2021 | |
Neoplasms | Preclinical | SE | 07 Jun 2021 | |
Gastrooesophageal junction cancer | Preclinical | - | - | |
Metastatic breast cancer | Preclinical | - | - | |
Non-Small Cell Lung Cancer | Preclinical | - | - |